(Alliance News) - Indivior PLC said Friday a US federal court in the Western District of Virginia has approved the agreement between the pharmaceuticals firm and the US Department of Justice over resolving criminal charges in the US related to its Suboxone film opioid dependence medication.
In mid-July, Indivior agreed to part with USD600 million to resolve the charges with the US Justice Department.
In April 2019 a grand jury in the Western District of Virginia had issued an indictment of 28 felony counts against the company related to fraud.
The felonies, issued in connection with a federal criminal investigation initiated by the US Department of Justice in 2013, include one count of conspiracy to commit mail, wire and health care fraud; one count of health care fraud; four counts of mail fraud; and 22 counts of wire fraud.
In a statement Friday, Indivior noted the federal court has dismissed all of these charges.
Indivior could have faced USD3 billion in fines related to the matters.
"As previously noted, Indivior is pleased to put this matter behind it and move forward in a manner that provides certainty to its business," the firm said Friday.
Previously, Indivior Solutions Inc, a wholly-owned subsidiary of Indivior PLC, pleaded guilty to one count of making a false statement relating to health care matters in 2012. As a result Indivior Solutions is now excluded from participating in US government health schemes, though the ban will not affect other Indivior subsidiaries.
Shares in Indivior were down 0.3% in London on Friday morning at 122.60 pence each.
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Indivior (INDV)